

Resource Summary Report

Generated by RRID on Sep 3, 2026

Vero E6-TMPRSS2-T2A-ACE2

RRID:CVCL_C7NK

Type: Cell Line

Proper Citation

BEI_Resources Cat# NR-54970, RRID:CVCL_C7NK

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_C7NK

Proper Citation: BEI_Resources Cat# NR-54970, RRID:CVCL_C7NK

Description: Cell line Vero E6-TMPRSS2-T2A-ACE2 is a Spontaneously immortalized cell line with a species of origin Chlorocebus sabaeus (Green monkey)

Sex: Female

Comments: Characteristics: Transfected with a PuroR-P2A-TMPRSS2-T2A-ACE2 plasmid under the control of a CAG promoter (BEI_Resources=NR-54970)., Group: SARS-CoV-2 research cell line., Group: Non-human primate cell line.

Category: Spontaneously immortalized cell line

Organism: Chlorocebus sabaeus (Green monkey)

Name: Vero E6-TMPRSS2-T2A-ACE2

Cross References: BEI_Resources:NR-54970, Wikidata:Q117704960

ID: CVCL_C7NK

Vendor: BEI_Resources

Catalog Number: NR-54970

Hierarchy: cvcl_0574

Record Creation Time: 20250130T073020+0000

Record Last Update: 20260904T021028+0000

Ratings and Alerts

No rating or validation information has been found for Vero E6-TMPRSS2-T2A-ACE2.

No alerts have been found for Vero E6-TMPRSS2-T2A-ACE2.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Slamanig S, et al. (2025) A single immunization with intranasal Newcastle disease virus (NDV)-based XBB.1.5 variant vaccine reduces disease and transmission in animals against matched-variant challenge. *Vaccine*, 45, 126586.

Uraki R, et al. (2025) An mRNA vaccine encoding the SARS-CoV-2 Omicron XBB.1.5 receptor-binding domain protects mice from the JN.1 variant. *EBioMedicine*, 117, 105794.

Klute S, et al. (2025) Mutation T9I in Envelope confers autophagy resistance to SARS-CoV-2 Omicron. *iScience*, 28(7), 112974.

Mao L, et al. (2024) Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19. *Med (New York, N.Y.)*, 5(1), 42.

Slamanig S, et al. (2024) Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice. *EBioMedicine*, 105, 105185.

de Vries M, et al. (2023) Generation of quality-controlled SARS-CoV-2 variant stocks. *Nature protocols*, 18(12), 3821.